Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

12/07/2012 | 08:00am US/Eastern

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
React to this article
Latest news
Date Title
10:56p MONSANTO : EDITORIAL: Missouri chamber once again gets discrimination all wrong
10:56pDJASIAN SHARES : Hong Kong Shares Rebound
10:55p SUDA : Clinical Advisory Board
10:50p Abitibi Royalties Inc. Receives First Cash Flow
10:49p BLACKROCK : China needs more reform to avert 'boom bust' market scenarios-BlackRock
10:49p PEUGEOT : Dongfeng, PSA Peugeot Citroen to deepen cooperation
10:48p ABITIBI ROYALTIES : VAN:RZZ) Receives First Cash Flow
10:45p KROGER : to open new store on May 13
10:45p MINISTRY OF FOREIGN AFFAIRS OF PEOPLE REPUBL : Li Keqiang Meets with President of Japanese Association for the Promotion of International Trade Kono Yohei
10:44p MILBERG LLP : Files Class Action Against AudioEye, Inc. Alleging Violations of U.S. Federal Securities Laws
Latest news
Advertisement
Hot News 
ANALYTIK JENA : New ICP-MS is Received with Great Interest at Analitica Expo in Moscow
FARO TECHNOLOGIES : Nasdaq stocks posting largest percentage decreases
MEDICINES : FDA Approves New Formulation of MINOCIN® (minocycline) for Injection
SHL TELEMEDICINE : comments on media reports about potential sale
CLIPPER LOGISTICS : Snaps Up Deal With Fashion Retailer Pep & Co
Most Read News
06:16p WAL MART STORES : Union seeks labor board injunction over Wal-Mart store closings
06:21p PLATTS : Pre-Report Survey of Analysts’ EIA/API Estimates Suggests a 2.6 Million-Barrel Build in U.S. Crude Oil Stocks
06:22p HORMEL FOODS : says bird flu outbreak will reduce its turkey sales; about 2.4M turkeys lost nationwide
06:02p Canada's Legacy Oil + Gas targeted by activist shareholder
06:21p PLATTS : JKM™ for May-delivered LNG Showed First Monthly Gain since November
Most recommended articles
10:49p BLACKROCK : China needs more reform to avert 'boom bust' market scenarios-BlackRock
10:36p Oil prices ease as U.S. stockpiles seen rising
10:31p Oil prices ease as U.S. stockpiles seen rising
10:24p Japan, U.S. sound optimistic on TPP trade pact negotiations
10:16pDJChina Resources Enterprise to Sell Non-Beer Assets
Dynamic quotes  
ON
| OFF